{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:35:36Z","timestamp":1784039736072,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Whilst small\u2010scale studies on rates of alloimmunisation of patients on Daratumumab have been undertaken, no large\u2010scale study has been performed to date on this cohort of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with multiple myeloma (MM) who are relapsed or refractory to standard treatment are treated with the anti\u2010CD38 therapeutic monoclonal antibody, Daratumumab. Due to the complexity of pre\u2010transfusion compatibility testing, many MM patients in England are referred to Red Cell Immunohaematology (RCI) laboratories for investigation and provision of Red Blood Cell (RBC) components.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Over a 4\u2010month period, patients due to commence, or currently on anti\u2010CD38 therapy were identified and flagged on the RCI Laboratory Information Management System (LIMS). Data was identified and extracted for further analysis. Interrogation of data was performed independently by two subject matter experts, with discrepancies resolved through further enquiry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 734 English MM patients, we report an alloimmunisation rate of 0.4% whilst on an anti\u2010CD38 TMAb. This is in line with other smaller cohort studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Given the low rate of RBC alloimmunisation, consideration should be given to revising the pre\u2010transfusion testing regimen in this cohort. This may improve testing costs, turn\u2010around times and evidence\u2010based patient care.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tme.12808","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T03:45:41Z","timestamp":1629258341000},"page":"474-480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Alloimmunisation rate of patients on <scp>Daratumumab<\/scp>: A retrospective cohort study of patients in <scp>England<\/scp>"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-0389","authenticated-orcid":false,"given":"Tom","family":"Bullock","sequence":"first","affiliation":[{"name":"Red Cell Immunohaematology, NHSBT, Filton Centre  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Foster","sequence":"additional","affiliation":[{"name":"Red Cell Immunohaematology, NHSBT, Newcastle Centre  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony","family":"Clinkard","sequence":"additional","affiliation":[{"name":"Clinical Audit, NHSBT, Filton Centre  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30222-0"},{"key":"e_1_2_7_3_1","unstructured":"NICE Technology Appraisal Guidance [TA510].Daratumumab monotherapy for treating relapsed and refractory multiple myeloma.https:\/\/www.nice.org.uk\/guidance\/ta510. Accessed May 21 2020."},{"key":"e_1_2_7_4_1","unstructured":"British Society for Haematology.Daratumumab combination therapy approved for relapsed multiple myeloma.https:\/\/b-s-h.org.uk\/about-us\/news\/daratumumab-combination-therapy-approved-for-relapsed-multiple-myeloma\/. Accessed May 21 2020."},{"key":"e_1_2_7_5_1","unstructured":"British National Formulary (BNF).Daratumumab.https:\/\/bnf.nice.org.uk\/drug\/daratumumab.html#drugAction. Accessed May 21 2020."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1515969"},{"key":"e_1_2_7_7_1","unstructured":"MilkinsC BerrymanJ CantwellC ElliottC HaggasR JonesJ RowleyM WilliamsM WinN.BSH Pre\u2010transfusion compatibility procedures in blood transfusion laboratories; Addendum (2017);2017.https:\/\/b-s-h.org.uk\/media\/15725\/monoclonal-antibodies-addendum.pdf. Accessed June 16 2020."},{"key":"e_1_2_7_8_1","unstructured":"NarayanS PolesD.The Serious Hazards of Transfusion (SHOT) Steering Groupet al.The 2018 Annual SHOT Report;2019."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069"},{"key":"e_1_2_7_10_1","volume-title":"Judd's Methods in Immunohematology","author":"Judd WJ","year":"2008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13174"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000495773"},{"issue":"3","key":"e_1_2_7_13_1","first-page":"26A","article-title":"Daratumumab\u2010derived anti\u2010CD38 can be easily mistaken for clinically significant antibodies to Lutheran antigens or to knops antigens (abstract)","volume":"55","author":"Velliquette RW","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.09.002"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2017.12.001"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2017.09.003"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12864"},{"key":"e_1_2_7_18_1","first-page":"102658","article-title":"Transfusion management in multiple myeloma patients receiving daratumumab: experience of a single tertiary care Centre","volume":"4","author":"Solves P","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14021"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15134"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12508"},{"issue":"6","key":"e_1_2_7_22_1","first-page":"1062","article-title":"High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh\u2010matched minority donors","volume":"122","author":"Chou ST","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00289.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00038.x"},{"issue":"3","key":"e_1_2_7_25_1","first-page":"980","article-title":"Is it necessary to administer anti\u2010D to prevent RhD immunization after the transfusion of RhD\u2010positive platelet concentrates?","volume":"111","author":"Atoyebi W","year":"2000","journal-title":"Br J Haematol"},{"key":"e_1_2_7_26_1","volume-title":"Cancer Incidence and Survival by Major Ethnic Group, England, 2002\u20132006","author":"Forman D","year":"2009"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tme.12808","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T16:55:51Z","timestamp":1693241751000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.12808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/tme.12808"],"URL":"https:\/\/doi.org\/10.1111\/tme.12808","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"2021-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}